Gene: QRFPR

84109
AQ27|GPR103|SP9155
pyroglutamylated RFamide peptide receptor
protein-coding
4q27
Ensembl:ENSG00000186867 MIM:606925 Vega:OTTHUMG00000133036 UniprotKB:Q96P65
NC_000004.12
SNP Mapped
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.479e-1 (AD)  1.603e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs523815chr4:121379140 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SAMD50.695
CNIH30.68
TRABD2A0.673
NRG10.672
RAB3B0.664
GABRG30.661
CORO2A0.658
GRM80.657
VWC2L0.657
TMEM1690.656

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
STON2-0.555
PARD3-0.527
CDC14A-0.521
NBPF10-0.517
NHSL1-0.501
STK17B-0.497
ARHGEF26-0.496
RFX2-0.495
RHOBTB3-0.494
IMPA2-0.492

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of QRFPR mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of QRFPR mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of QRFPR mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of QRFPR mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of QRFPR mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QRFPR mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QRFPR mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QRFPR mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QRFPR mRNA"27188386
C015001arsenitearsenite results in decreased expression of QRFPR mRNA23974009
C006780bisphenol Abisphenol A results in decreased expression of QRFPR mRNA25181051
C584509C646 compoundC646 compound results in increased expression of QRFPR mRNA26191083
C100187chloropicrinchloropicrin results in increased expression of QRFPR mRNA26352163
D003300CopperCopper deficiency results in increased expression of QRFPR mRNA26033743
D005473FluoxetineFluoxetine results in decreased expression of QRFPR mRNA21820738
D004397FonofosFonofos results in increased methylation of QRFPR promoter22847954
C492448ICG 001ICG 001 results in increased expression of QRFPR mRNA26191083
C500085muraglitazarmuraglitazar results in decreased expression of QRFPR mRNA21515302
D010278ParathionParathion results in increased methylation of QRFPR promoter22847954
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of QRFPR mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QRFPR mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of QRFPR mRNA26272509
D011441PropylthiouracilPropylthiouracil results in increased expression of QRFPR mRNA24780913
C089730rosiglitazonerosiglitazone results in decreased expression of QRFPR mRNA21515302
C012568terbufosterbufos results in increased methylation of QRFPR promoter22847954
C501413tesaglitazartesaglitazar results in decreased expression of QRFPR mRNA21515302
C024746tobacco tartobacco tar results in increased expression of QRFPR mRNA19559774
C057693troglitazonetroglitazone results in decreased expression of QRFPR mRNA21515302
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QRFPR mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of QRFPR mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of QRFPR mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004930G-protein coupled receptor activity-IDA12960173  
GO:0004983neuropeptide Y receptor activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007186G-protein coupled receptor signaling pathway-IDA12960173  
GO:0007186G-protein coupled receptor signaling pathway-TAS-  
GO:0007218neuropeptide signaling pathway-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0016021integral component of membrane-IC12960173  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-373076Class A/1 (Rhodopsin-like receptors)TAS
R-HSA-375276Peptide ligand-binding receptorsTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-389397Orexin and neuropeptides FF and QRFP bind to their respective receptorsTAS
R-HSA-416476G alpha (q) signalling eventsTAS
R-HSA-500792GPCR ligand bindingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal